Jin Medical International (ZJYL) Cash & Equivalents (2022 - 2025)

Jin Medical International (ZJYL) has reported Cash & Equivalents for 4 consecutive years, with $7.5 million the latest figure, recorded in Q3 2025.

• Quarterly Cash & Equivalents fell 8.29% year-over-year to $7.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.5 million (down 8.29% YoY) and the FY2025 annual result came in at $7.5 million, down 8.29% from the prior year.
• Cash & Equivalents eased to $7.5 million in Q3 2025 per ZJYL's latest filing, from $11.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ZJYL reached as high as $11.1 million in Q1 2025 and fell as low as $4.8 million in Q3 2022.
• A 4-year average of $8.0 million and a median of $8.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 44.59% — and 2025, when it retreated 8.29%.
• Year by year, Cash & Equivalents stood at $4.8 million in 2022, then soared by 44.59% to $6.9 million in 2023, then gained by 17.41% to $8.1 million in 2024, then slipped by 8.29% to $7.5 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.5 million, $11.1 million, and $8.1 million for Q3 2025, Q1 2025, and Q3 2024 respectively.